Molecule of the Week


October 25, 2010

Crizotinib is a drug being developed by Pfizer to treat lung cancer, particularly non–small cell lung carcinoma that most frequently affects younger nonsmokers or former light smokers. Its mode of action is to inhibit the enzyme anaplastic lymphoma kinase (ALK). In a recent Phase I/II trial, crizotinib performed exceptionally well, and a Phase III trial is under way.

More about this molecule from CAS, the most authoritative and comprehensive source for chemical information.